ZYMEWORKS INC (ZYME)
US98985Y1082 - Common Stock
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors...
ZYME Crosses Below Key Moving Average Level
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors...
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a...
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors...
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)
Zymeworks Becomes Oversold (ZYME)
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a...
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a...
Next-Gen Winners: 7 Tech Stocks Set to Dominate the Decade
Explore top tech stocks to dominate the decade, with their fundamental leading in information technology, finance, and health care.
ZYME Stock Earnings: Zymeworks Beats EPS, Beats Revenue for Q4 2023
ZYME stock results show that Zymeworks beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
ZYME Stock Earnings: Zymeworks Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zymeworks (NASDAQ:ZYME) just reported results for the fourth quarter of 2023.Zy...
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a summary of recent business highlights.
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product...
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.
Last Call! 7 Small-Cap Stocks Ready to Explode in Value
Discover the small-cap stocks in the telecommunications, biotech, research, silver, transportation, and trading, ready to explode in value.
Commit To Buy Zymeworks At $10, Earn 16.7% Annualized Using Options
7 Small-Cap Stocks With Significant Upside Potential in 2024
Dive into small-cap stocks for a mix of stability & growth, wagering on potential leaders before the market catches on.
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
3 Top Stocks to Buy This Winter for Sizzling Summer Gains
With economic momentum accelerating, these three top stocks flying under Wall Street's radar seem poised for sizzling summer gains.